What's Going On With Tharimmune Shares Wednesday?
Portfolio Pulse from Dylan Berman
Tharimmune, Inc. (NASDAQ:THAR) shares surged over 100% after receiving positive feedback from the European Medicines Agency (EMA) on its TH104 clinical program for treating pruritus in primary biliary cholangitis. The EMA approved the design of the Phase 2 study and provided guidance for Phase 3. Tharimmune plans to start a Phase 2 trial soon, with results expected in 2025.
October 30, 2024 | 4:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tharimmune's stock price more than doubled after the EMA provided positive feedback on its TH104 clinical program. The EMA's approval of the Phase 2 study design and guidance for Phase 3 are significant milestones for the company.
The EMA's positive feedback is a critical regulatory milestone, boosting investor confidence and driving the stock price up by 107.9%. The approval of the Phase 2 study design and guidance for Phase 3 are pivotal for the company's future prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100